London, October 27, 2022 (GLOBE NEWSWIRE) — root analysis has the addition of “Adeno-associated viral vector / AAV vector Market, 2022-2035” Report on his offer list.
Because of their unique biology, simple structure, and lack of disease correlation, the adeno-associated viral vectors have attracted great interest in the medical community. In fact, various adeno-associated viral vector-based therapies have been developed for the treatment of multiple indications, including retinitis pigmentosa, cystic fibrosis, and Duchenne muscular dystrophy. As a result, the demand for such vectors has increased tremendously, creating lucrative opportunities for the players operating in the adeno-associated viral vectors market.
To order this 250+ page report with 150+ figures and 225+ tables, please visit https://www.rootsanalysis.com/reports/adeno-associated-viral-vector-market.html
Key Market Insights
More than 550 adeno-associated viral vector/AAV vector-based therapies have been/are being evaluated at various stages of development for the treatment of various diseases
Nearly 20% of the candidates in the pipeline are in clinical testing; The majority (26%) of these candidates are being developed for the treatment of neurological disorders, followed by candidates being evaluated for the treatment of eye disorders (21%).
Over 80 industry stakeholders claim to have the skills needed to produce Adeno-Associated Viral Vectors / AAV Vectors
The market is currently dominated by the presence of various medium-sized industrial companies (53%); Of these, 65% of players have their own manufacturing capabilities, while 44% of players are contract manufacturers.
Over 30 stakeholders are involved in the development of adeno-associated viral vector/AAV vector platforms
More than 90% of these players offer their technologies for gene therapy, followed by those offering cell therapy platforms (23%). It is worth noting that two…
